Stark D D, Weissleder R, Elizondo G, Hahn P F, Saini S, Todd L E, Wittenberg J, Ferrucci J T
Department of Radiology, Massachusetts General Hospital, Boston 02114.
Radiology. 1988 Aug;168(2):297-301. doi: 10.1148/radiology.168.2.3393649.
Superparamagnetic iron oxide (ferrite) particles were evaluated as a contrast agent for magnetic resonance (MR) imaging. In this pilot study, doses ranging from 10 to 50 mumol/kg were administered intravenously to 15 patients. Ferrite-enhanced images of the liver obtained with standard pulse sequence techniques significantly increased the number of hepatic lesions detected (P less than .01) and reduced the threshold size for detection to 3 mm (P less than .01). The improved clinical performance of ferrite-enhanced images correlated with significant increases in measured contrast-to-noise ratios (P less than .01). Degradation of superparamagnetic activity and/or clearance of ferrite from the liver was demonstrated as early as 12 hours after injection, suggesting that the lack of chronic toxicity observed in animal studies may be reproduced in humans. These initial clinical results appear to confirm extensive preclinical data indicating that ferrite administered at a dose of 20 mumol/kg has the potential to significantly improve the performance of abdominal MR imaging.
超顺磁性氧化铁（铁氧体）颗粒被评估作为磁共振（MR）成像的造影剂。在这项初步研究中，给15名患者静脉注射了10至50μmol/kg的剂量。用标准脉冲序列技术获得的肝脏铁氧体增强图像显著增加了检测到的肝脏病变数量（P<0.01），并将检测阈值大小降低到3mm（P<0.01）。铁氧体增强图像临床性能的改善与测量的对比噪声比显著增加相关（P<0.01）。早在注射后12小时就证明了超顺磁性活性的降解和/或铁氧体从肝脏的清除，这表明在动物研究中观察到的缺乏慢性毒性可能在人类中重现。这些初步临床结果似乎证实了广泛的临床前数据，表明以20μmol/kg的剂量给药的铁氧体有可能显著改善腹部MR成像的性能。
